Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,269.23 -8.28 (-0.16%) Dow
38,411.42 -274.90 (-0.71%) Nasdaq
16,800.12 +65.11 (+0.39%) Bitcoin USD
69,268.11 +1,199.59 (+1.76%) CMC Crypto 200
1,488.89 +20.95 (+1.43%)
TEVA Dec 2024 15.000 call
| Previous close | 3.0100 |
| Open | 3.1000 |
| Bid | 3.2500 |
| Ask | 3.3500 |
| Strike | 15.00 |
| Expiry date | 2024-12-20 |
| Day's range | 3.0100 - 3.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 329 |
Business WireNew Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
TEL AVIV, Israel & PARSIPPANY, N.J., June 01, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of seven studies from its long-acting injectable (LAI) schizophrenia research program. Presentations include data informing clinical strategies for switching patients to UZEDY, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia
Business WireTeva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
TEL AVIV, Israel & PARSIPPANY, N.J., June 01, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new patient- and physician-reported interim results from the Phase 4 IMPACT-TD Registry study, reinforcing that TD has a wide-reaching, multidimensional impact on patients’ quality of life. These interim findings from the IMPACT-TD study were presented at the 2024 Psych Congress Elevate Annual Meeting, taking place from May 30 –
Business WireTeva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)
TEL AVIV, Israel & PARSIPPANY, N.J., May 29, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved AUSTEDO XR as a one pill, once-daily treatment option, now with four new tablet strengths (30, 36, 42, 48 mg) indicated in adults for TD and HD chorea.
